Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice

Bichoy H. Gabra, Vanessa Merino, Michael Bader, João B. Pesquero, Pierre Sirois

Research output: Contribution to journalArticle

Abstract

Experimental evidence has shown that the inducible bradykinin (BK) B 1 receptor (BKB1-R) subtype is involved in the development of hyperalgesia associated with type 1 diabetes. Selective BKB1-R antagonists inhibited, whereas selective agonists increased the hyperalgesic activity in diabetic mice in thermal nociceptive tests. Here we evaluate the development of diabetic hyperalgesia in a BKB1-R-knockout (KO) genotype compared to wild-type (WT) mice. The BKB1-R-KO mice were backcrossed for 10 generations to C57BL/6 genetic background before use in the experiments. Diabetes was induced by streptozotocin (STZ) and thermal nociception was assessed by the hot plate and tail immersion tests. The hyperalgesia observed in wild type mice was totally absent in the BKB 1-R-KO mice. Furthermore, the selective BKB1-R agonist, desArg9BK, significantly increased the hyperalgesic activity in diabetic WT mice but had no effect on nociceptive responses in diabetic BKB 1-R-KO mice. Taken together, the results confirm the crucial role of the BKB1-R, upregulated alongside inflammatory diabetes, in the development of diabetes-induced hyperalgesia.

Original languageEnglish (US)
Pages (from-to)245-248
Number of pages4
JournalRegulatory Peptides
Volume127
Issue number1-3
DOIs
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Bradykinin B1 Receptors
Hyperalgesia
Medical problems
Knockout Mice
Hot Temperature
Nociception
Bradykinin
Immersion
Streptozocin
Type 1 Diabetes Mellitus
Tail
Genotype
Experiments

Keywords

  • Bradykinin B receptor
  • DesArgbradykinin
  • Hyperalgesia
  • Kinins
  • R-715
  • R-954
  • Type 1 diabetes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice. / Gabra, Bichoy H.; Merino, Vanessa; Bader, Michael; Pesquero, João B.; Sirois, Pierre.

In: Regulatory Peptides, Vol. 127, No. 1-3, 15.04.2005, p. 245-248.

Research output: Contribution to journalArticle

Gabra, Bichoy H. ; Merino, Vanessa ; Bader, Michael ; Pesquero, João B. ; Sirois, Pierre. / Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice. In: Regulatory Peptides. 2005 ; Vol. 127, No. 1-3. pp. 245-248.
@article{7dd758d666f444adae98ca89033a3847,
title = "Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice",
abstract = "Experimental evidence has shown that the inducible bradykinin (BK) B 1 receptor (BKB1-R) subtype is involved in the development of hyperalgesia associated with type 1 diabetes. Selective BKB1-R antagonists inhibited, whereas selective agonists increased the hyperalgesic activity in diabetic mice in thermal nociceptive tests. Here we evaluate the development of diabetic hyperalgesia in a BKB1-R-knockout (KO) genotype compared to wild-type (WT) mice. The BKB1-R-KO mice were backcrossed for 10 generations to C57BL/6 genetic background before use in the experiments. Diabetes was induced by streptozotocin (STZ) and thermal nociception was assessed by the hot plate and tail immersion tests. The hyperalgesia observed in wild type mice was totally absent in the BKB 1-R-KO mice. Furthermore, the selective BKB1-R agonist, desArg9BK, significantly increased the hyperalgesic activity in diabetic WT mice but had no effect on nociceptive responses in diabetic BKB 1-R-KO mice. Taken together, the results confirm the crucial role of the BKB1-R, upregulated alongside inflammatory diabetes, in the development of diabetes-induced hyperalgesia.",
keywords = "Bradykinin B receptor, DesArgbradykinin, Hyperalgesia, Kinins, R-715, R-954, Type 1 diabetes",
author = "Gabra, {Bichoy H.} and Vanessa Merino and Michael Bader and Pesquero, {Jo{\~a}o B.} and Pierre Sirois",
year = "2005",
month = "4",
day = "15",
doi = "10.1016/j.regpep.2004.12.003",
language = "English (US)",
volume = "127",
pages = "245--248",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice

AU - Gabra, Bichoy H.

AU - Merino, Vanessa

AU - Bader, Michael

AU - Pesquero, João B.

AU - Sirois, Pierre

PY - 2005/4/15

Y1 - 2005/4/15

N2 - Experimental evidence has shown that the inducible bradykinin (BK) B 1 receptor (BKB1-R) subtype is involved in the development of hyperalgesia associated with type 1 diabetes. Selective BKB1-R antagonists inhibited, whereas selective agonists increased the hyperalgesic activity in diabetic mice in thermal nociceptive tests. Here we evaluate the development of diabetic hyperalgesia in a BKB1-R-knockout (KO) genotype compared to wild-type (WT) mice. The BKB1-R-KO mice were backcrossed for 10 generations to C57BL/6 genetic background before use in the experiments. Diabetes was induced by streptozotocin (STZ) and thermal nociception was assessed by the hot plate and tail immersion tests. The hyperalgesia observed in wild type mice was totally absent in the BKB 1-R-KO mice. Furthermore, the selective BKB1-R agonist, desArg9BK, significantly increased the hyperalgesic activity in diabetic WT mice but had no effect on nociceptive responses in diabetic BKB 1-R-KO mice. Taken together, the results confirm the crucial role of the BKB1-R, upregulated alongside inflammatory diabetes, in the development of diabetes-induced hyperalgesia.

AB - Experimental evidence has shown that the inducible bradykinin (BK) B 1 receptor (BKB1-R) subtype is involved in the development of hyperalgesia associated with type 1 diabetes. Selective BKB1-R antagonists inhibited, whereas selective agonists increased the hyperalgesic activity in diabetic mice in thermal nociceptive tests. Here we evaluate the development of diabetic hyperalgesia in a BKB1-R-knockout (KO) genotype compared to wild-type (WT) mice. The BKB1-R-KO mice were backcrossed for 10 generations to C57BL/6 genetic background before use in the experiments. Diabetes was induced by streptozotocin (STZ) and thermal nociception was assessed by the hot plate and tail immersion tests. The hyperalgesia observed in wild type mice was totally absent in the BKB 1-R-KO mice. Furthermore, the selective BKB1-R agonist, desArg9BK, significantly increased the hyperalgesic activity in diabetic WT mice but had no effect on nociceptive responses in diabetic BKB 1-R-KO mice. Taken together, the results confirm the crucial role of the BKB1-R, upregulated alongside inflammatory diabetes, in the development of diabetes-induced hyperalgesia.

KW - Bradykinin B receptor

KW - DesArgbradykinin

KW - Hyperalgesia

KW - Kinins

KW - R-715

KW - R-954

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=13144250172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13144250172&partnerID=8YFLogxK

U2 - 10.1016/j.regpep.2004.12.003

DO - 10.1016/j.regpep.2004.12.003

M3 - Article

VL - 127

SP - 245

EP - 248

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -